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ABSTRACT
Turicella otitidis is a non-fermenting Gram-posit-
ive bacillus isolated almost exclusively from ear
exudates. Its significance in acute or chronic otitis
media is controversial. Over a 12-month period,
T. otitidis was isolated from nine ear exudates
from seven patients. Most of these were cases of
spontaneous drainage following recurrence of
otitis media after antimicrobial therapy that was
ineffective against T. otitidis. The MICs of penicil-
lin, levofloxacin, linezolid and vancomycin were
very low for all the isolates studied, but most
isolates displayed high resistance to macrolides
and lincosamides.
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Acute exudative otitis media is an inflammatory
process with the presence of fluid in the middle
ear, accompanied by fever and acute local pain.
Chronic otitis media is characterised by recurrent
episodes of variable duration, accompanied by
the production of exudate in the middle ear, and
may lead to perforation of the tympanic mem-
brane [1]. The fluid in the middle ear may persist
for considerable periods of time, and paediatric
patients with this pathology may have reduced
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learning ability with reference to language man-
agement and other cognitive activities [2].
The role played by microbial pathogens in this
condition is open to debate, but it seems clear that
the isolation of organisms such as Streptococcus
pneumoniae or Haemophilus influenzae is related
directly to reoccurrence of infection in these
patients [3]. However, following spontaneous or
therapeutic perforation of the ear drum, it is not
unusual to find colonisation by members of the
normal flora of the external auditory canal, such
as staphylococci and coryneforms, whose role in
the exacerbations of the illness is unclear.
Of the latter, Turicella otitidis, a non-fermenting
Gram-positive bacillus, may be associated with
otitis media, although the degree of its participa-
tion is controversial. The literature contains a
number of reports of middle ear pathology and
concomitant isolation of T. otitidis [4–6]. Most
cases involve children aged < 3 years, and the
organism is isolated in either pure or mixed
culture. Other reports of infections have involved
a cervical abscess, a mastoiditis, an auricular
abscess with repeated episodes of otitis media,
and a case of bacteraemia in a patient with malign
haemopathy [7–10].
In a 12-month period (June 2001 to June 2002),
our laboratory processed 153 ear exudates,
obtained directly by tympanocentesis or from
the external auditory canal of 112 patients with
clinical symptoms of acute exudative otitis media
or exacerbations of chronic otitis media, and
performed an active search for coryneform bac-
teria. Identification of the organisms obtained was
done with the API Coryne, API Zym and API 50
CH systems (bioMe´rieux, Marcy l’Etoile, France),
together with standard morphological and phen-
otypic tests. Sensitivities were determined with
Etests (AB Biodisk, Solna, Sweden) with an
inoculum of 0.5· McFarland standard on plates
of Mueller–Hinton agar supplemented with sheep
blood 5% v ⁄ v.
Cultures from 54 patients were negative or grew
non-significant isolates. Potentially significant iso-
lates were obtained from the other 58 patients,
namely Staphylococcus aureus, Pseudomonas aerugi-
nosa, enterobacteria, H. influenzae, S. pneumoniae,
Branhamella catarrhalis, Alloiococcus otitidis and
T. otitidis. Nine isolates of T. otitidis were obtained
from seven patients aged 6 months–7 years with
middle ear pathologies. The organism was re-
isolated from two of these patients 2 and 6 months
later, respectively. Details of the seven patients are
summarised in Table 1.
T. otitidis was described originally in 1994 by
Funke et al. [11], and is characterised by long,
unbranching Gram-positive bacilli which form
2-mm, non-haemolytic colonies after incubation
for 24 h on blood agar, with a creamy appearance,
which may resemble small colonies of coagulase-
negative staphylococci. The addition of Tween-80
to the medium does not stimulate growth of the
organism, thereby demonstrating its non-lipophi-
lic nature [6]. T. otitidis is catalase-, alkaline
phosphatase- and pirazinamidase-positive, non-
motile, does not reduce nitrates, lacks urease, and
has an oxidative metabolism for carbohydrates.
The numerical profile in the API Coryne system is
almost invariably 210004, a code shared with
Corynebacterium auris and Corynebacterium afer-
mentans [11]. Although final identification
requires complex tests not employed habitually
in the clinical laboratory, a distinction between
T. otitidis and the above microorganisms may be
made on the basis of relatively simple morpholo-
gical and metabolical characteristics (Table 2).
Table 1. Cases of otitis media from which Turicella otitidis was isolated
Patient
number
Age
(years)
Other organisms
isolated Drainage
Previous
therapy
MIC (mg ⁄L) for T. otitidis isolate
ERY AZY CLI PEN LIN LEV VAN
1 3 Staphylococcus
aureus, CNS
Spontaneous No data > 256 > 256 > 256 < 0.03 0.064 0.125 0.5
2 2 None Tympanocentesis None < 0.016 < 0.016 0.032 < 0.03 0.064 0.064 0.5
3 1.5 Staphylococcus
aureus
Spontaneous No data > 256 > 256 > 256 0.06 0.064 0.064 0.5
4 1.4 None Spontaneous ERY > 256 > 256 0.5 < 0.03 0.064 0.125 0.5
5 0.5 Alloicoccus
otitidis
Tympanocentesis None > 256 > 256 > 256 0.25 0.125 1 0.5
6 6 CNS Spontaneous AZY > 256 > 256 > 256 0.06 0.125 0.25 0.5
7 7 Corynebacterium
afermentans, CNS
Spontaneous AMP +
GEN
< 0.016 < 0.016 0.064 < 0.03 0.064 0.25 0.75
AMP, ampicillin; AZY, azithromycin; CLI, clindamycin; CNS, coagulase-negative Staphylococcus; ERY, erythromycin; GEN, gentamicin; LEV, levofloxacin; LIN, linezolid;
VAN, vancomycin.
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The role played by T. otitidis in middle ear
pathology is controversial, as it can be isolated
from the external auditory canal of healthy subjects
[12,13]. Holzmann et al. [14] isolated T. otitidis from
14 (23.3%) of 60 children with exudative otitis
media by means of tympanocentesis, and from the
external auditory canal of 23 (11.2%) of 205 healthy
children, suggesting that T. otitidis is simply a part
of the habitual flora of the external auditory canal.
The habitat of T. otitidis seems to be confined almost
exclusively to the ear or adjoining areas, and
T. otitidis does not appear to form part of the
commensal flora at any other anatomical site [11]. It
is possible that T. otitidis may play a role in ear
infections as coloniser or pathogen according to the
environmental conditions in the area colonised.
Thus, local immunological alterations and ⁄ or
imbalances in the accompanying flora caused by
inflammatory processes and ⁄ or the administration
of antimicrobial agents may facilitate the over-
growth and extension of previously colonising
organisms which, on occasion, may become genu-
ine pathogens.
The seven cases described here represent two
different clinical situations. Two patients, num-
bers 2 and 4, were children with acute episodes of
otitis media who had not received previous
antimicrobial treatment, and from whom T. otit-
idis was isolated after tympanocentesis in pure
culture or with another potential pathogen speci-
fic to the ear, namely A. otitidis. In the other five
cases, the organism was isolated from sponta-
neous ear drainage in patients with well-docu-
mented previous episodes of the same pathology,
mostly including visible perforations of the ear
drum. In four of these five cases, T. otitidis was
isolated together with other members of the
normal flora of the external auditory canal. In
three of these five cases, the patients were
receiving, or had received recently, antimicrobial
treatment with agents probably inactive against
T. otitidis. Precise information was not available
for the other two patients.
Data in the literature regarding the susceptibil-
ity of T. otitidis to different antimicrobial agents
are scarce. The available data suggest susceptibil-
ity to most b-lactams, ciprofloxacin, rifampicin,
tetracycline and gentamicin, but there appears to
be significant resistance to macrolides and lincos-
amides [15,16]. Table 1 lists the susceptibilities of
the isolates from the present study, which broadly
followed the same pattern. Five of the seven
isolates were highly resistant to erythromycin and
azithromycin (MICs > 256 mg ⁄L) and were exam-
ined by PCR for the presence of genetic determi-
nants belonging to the erm family [17]. Neither the
ermA or ermTR genes were found, but this does
not exclude the presence of other related deter-
minants. Susceptibility to clindamycin was
equally bimodal, suggesting the possibility of an
active efflux pump for macrolides in this strain,
perhaps similar to those described in other Gram-
positive organisms.
In conclusion, T. otitidis is an easily recognised
and well-defined microorganism whose import-
ance in middle ear pathologies, especially
in recurrent chronic otitis media, remains contro-
versial. As with other coryneform bacteria, fur-
ther studies are required to define its precise
clinical role.
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Test C. afermentans C. auris T. otitidis
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bacilli arranged in V
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Gram-positive bacilli,
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Negative Positive Positive
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MIC: < 0.1 mg ⁄L
Frequently
resistant
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resistant
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ABSTRACT
NVP PDF-713 (LBM 415) is a peptide deformylase
inhibitor being progressed into clinical trials. Dry-
form broth microdilution panels of NVP PDF-713
were compared to reference MIC panels of 552
recent clinical isolates. Most (99.2%) dry-form
MIC results were within ± 1 log2 dilution of the
reference panel MICs. Of the bacteria tested,
Streptococcus pneumoniae and Haemophilus influen-
zae showed a bias towards higher and lower
MICs, respectively. Same-day and between-day
reproducibility tests showed that 98.9% and
96.7% of MIC values, respectively, were within
± 1 log2 dilution step, thereby demonstrating a
high degree of reliability of the dry-form MIC
product for clinical studies.
Keywords Broth microdilution panels, LBM 415, MIC
testing, NVP PDF-713, peptide inhibitor
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NVP PDF-713 (LBM 415) (Novartis Pharmaceuti-
cals, Basel, Switzerland) is one of the first inhib-
itors of the bacterial enzyme peptide deformylase
(PDF) to be progressed into human clinical trials
for the oral or parenteral treatment of community-
acquired respiratory tract infections and serious
infections caused by susceptible Gram-positive
pathogens. PDF is required in bacteria for protein
maturation, but is not found in eukaryotic cells,
making it an attractive target with a new mech-
anism of action for inhibition by antibacterial
agents [1,2]. In addition to documented activity
against major respiratory tract pathogens, inclu-
ding Streptococcus pneumoniae, Haemophilus influ-
enzae, Moraxella catarrhalis, Chlamydia pneumoniae
and Staphylococcus aureus, NVP PDF-713 has
appropriate oral bioavailability, pharmacokinetic
parameters and safety, making it an excellent
candidate for further clinical study and develop-
ment. PDF inhibitors are less active generally
against most Gram-negative species, with the
exception of anaerobes and the species mentioned
above [3,4]. NVP PDF-713 retains activity against
penicillin-resistant Strep. pneumoniae, methicillin-
resistant S. aureus and vancomycin-resistant en-
terococci. Fortuitously, cross-resistance with other
classes of antimicrobials has not been detected [5].
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